sb 203580 has been researched along with ropivacaine in 2 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (ropivacaine) | Trials (ropivacaine) | Recent Studies (post-2010) (ropivacaine) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 3,869 | 1,982 | 1,857 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colvin, HP; Gerner, P; Haller, I; Klimaschewski, L; Lang, L; Lirk, P; Tomaselli, B | 1 |
| Chen, Y; Song, Z; Sun, Z; Wang, E; Ye, Z; Zhang, Z | 1 |
2 other study(ies) available for sb 203580 and ropivacaine
| Article | Year |
|---|---|
In vitro, inhibition of mitogen-activated protein kinase pathways protects against bupivacaine- and ropivacaine-induced neurotoxicity.
Topics: Amides; Anesthetics, Local; Animals; Anthracenes; Bupivacaine; Butadienes; Cell Size; Cell Survival; Cells, Cultured; Cytoprotection; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Ganglia, Spinal; Imidazoles; JNK Mitogen-Activated Protein Kinases; Lidocaine; Membrane Potentials; Mitogen-Activated Protein Kinases; Neurons, Afferent; Nitriles; p38 Mitogen-Activated Protein Kinases; Phenotype; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Ropivacaine; Sodium Channels | 2008 |
[P38 MAPK inhibitor SB203580 attenuates the toxicity of ropivacaine on PC12 cells].
Topics: Anesthetics, Local; Animals; Apoptosis; Imidazoles; p38 Mitogen-Activated Protein Kinases; PC12 Cells; Pyridines; Rats; Ropivacaine | 2019 |